PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease (AD) and other neurodegenerative diseases, today announces a new epigenetics collaboration with Sheffield Hallam University.
PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease (AD) and other neurodegenerative diseases, today announces a new epigenetics collaboration with Sheffield Hallam University.